Reuters logo
BRIEF-U.S. FDA updates on Pfizer drug shortages
June 15, 2017 / 10:34 PM / 5 months ago

BRIEF-U.S. FDA updates on Pfizer drug shortages

June 15 (Reuters) - U.S. FDA :

* Says it is aware of the ongoing shortage situation affecting several injectable drugs, manufactured by Hospira, a Pfizer company

* Says Pfizer has reported the shortage is caused by manufacturing, distribution and third party delays

* Says it is working closely with Pfizer to resolve critical shortages by addressing underlying causes

* Says working to relieve these shortages through a variety of measures, including finding alternative manufacturers of these drug products

* Says continues to explore all available options to relieve shortages, which may include expediting review of applications or other submissions

* Says it may also consider temporary regulatory flexibility for alternative sources to relieve shortages as it continues to explore options

* Says shortage affecting injectable drugs, including sodium bicarbonate injection (vials & syringes), dextrose 50% injection (vials & syringes)

* Says shortage also affecting emergency syringes of drugs, including epinephrine, calcium chloride and atropine sulfate Source text : (bit.ly/2t7RTVS) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below